WallStreetZenWallStreetZen

NYSE: SOLV
Solventum Corp Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for SOLV

Based on 8 analysts offering 12 month price targets for Solventum Corp

Min Forecast
$60.00-8.12%
Avg Forecast
$90.50+38.59%
Max Forecast
$105.00+60.8%

Should I buy or sell SOLV stock?

Based on 8 analysts offering ratings for Solventum Corp.

Buy
Strong Buy
4 analysts 50%
Buy
1 analysts 12.5%
Hold
2 analysts 25%
Sell
0 analysts 0%
Strong Sell
1 analysts 12.5%
Although SOLV's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates SOLV as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their SOLV stock forecasts and price targets.

SOLV stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-03-24
lockedlocked$00.00+00.00%2026-02-27
lockedlocked$00.00+00.00%2026-02-27
lockedlocked$00.00+00.00%2026-02-27
lockedlocked$00.00+00.00%2026-01-20
Stifel Nicolaus
Top 14%
87
Strong BuyMaintains$105.00+60.80%2026-01-07
UBS
Top 21%
80
HoldMaintains$79.00+20.98%2025-11-10
Piper Sandler
Bottom 3%
3
Strong BuyMaintains$98.00+50.08%2025-11-07

1 of 1

Forecast return on equity

Is SOLV forecast to generate an efficient return?

Company
N/A
Industry
23.4%
Market
179.33%

Forecast return on assets

Is SOLV forecast to generate an efficient return on assets?

Company
N/A
Industry
17.97%

SOLV earnings per share forecast

What is SOLV's earnings per share in the next 3 years based on estimates from 16 analysts?

Avg 1 year Forecast
$6.57-26.52%
Avg 2 year Forecast
$7.18-19.73%
Avg 3 year Forecast
$7.91-11.53%
SOLV's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

SOLV revenue forecast

What is SOLV's revenue in the next 3 years based on estimates from 16 analysts?

Avg 1 year Forecast
$8.3B+0.12%
Avg 2 year Forecast
$8.6B+3.77%
Avg 3 year Forecast
$9.0B+7.84%
SOLV's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

SOLV earnings growth forecast

How is SOLV forecast to perform vs Health Information Services companies and vs the US market?

Company
-4.12%
Industry
31.8%
Market
36.24%
SOLV's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
SOLV's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
SOLV's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

SOLV revenue growth forecast

How is SOLV forecast to perform vs Health Information Services companies and vs the US market?

Company
2.52%
Industry
9.56%
Market
13.54%
SOLV's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
SOLV's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

SOLV vs Health Information Service Stocks

TickerPricePrice TargetUp/downsideConsensus
SOLV$65.30$90.50+38.59%Buy
BTSG$42.61$47.78+12.13%Strong Buy
TEM$45.22$76.90+70.06%Buy
HQY$83.57$111.70+33.66%Buy
WAY$24.11$35.14+45.76%Strong Buy
View Top Health Information Service Stocks

Solventum Stock Forecast FAQ

Is Solventum Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 8 Wall Street analysts covering (NYSE: SOLV) stock is to Buy SOLV stock.

Out of 8 analysts, 4 (50%) are recommending SOLV as a Strong Buy, 1 (12.5%) are recommending SOLV as a Buy, 2 (25%) are recommending SOLV as a Hold, 0 (0%) are recommending SOLV as a Sell, and 1 (12.5%) are recommending SOLV as a Strong Sell.

If you're new to stock investing, here's how to buy Solventum stock.

What is SOLV's earnings growth forecast for 2026-2028?

(NYSE: SOLV) Solventum's forecast annual earnings growth rate of -4.12% is not forecast to beat the US Health Information Services industry's average forecast earnings growth rate of 31.8%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.24%.

Solventum's earnings in 2026 is $1,556,000,000.On average, 16 Wall Street analysts forecast SOLV's earnings for 2026 to be $1,139,623,502, with the lowest SOLV earnings forecast at $1,074,546,276, and the highest SOLV earnings forecast at $1,185,911,436. On average, 15 Wall Street analysts forecast SOLV's earnings for 2027 to be $1,245,055,201, with the lowest SOLV earnings forecast at $1,117,052,062, and the highest SOLV earnings forecast at $1,377,187,474.

In 2028, SOLV is forecast to generate $1,372,173,526 in earnings, with the lowest earnings forecast at $1,207,164,329 and the highest earnings forecast at $1,573,928,541.

What is SOLV's revenue growth forecast for 2026-2028?

(NYSE: SOLV) Solventum's forecast annual revenue growth rate of 2.52% is not forecast to beat the US Health Information Services industry's average forecast revenue growth rate of 9.56%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.54%.

Solventum's revenue in 2026 is $8,325,000,000.On average, 16 Wall Street analysts forecast SOLV's revenue for 2026 to be $1,446,064,196,675, with the lowest SOLV revenue forecast at $1,373,023,641,570, and the highest SOLV revenue forecast at $1,498,632,577,190. On average, 16 Wall Street analysts forecast SOLV's revenue for 2027 to be $1,498,806,070,195, with the lowest SOLV revenue forecast at $1,420,213,738,930, and the highest SOLV revenue forecast at $1,569,244,230,225.

In 2028, SOLV is forecast to generate $1,557,620,198,890 in revenue, with the lowest revenue forecast at $1,463,066,511,165 and the highest revenue forecast at $1,652,694,365,630.

What is SOLV's forecast return on assets (ROA) for 2026-2029?

(NYSE: SOLV) forecast ROA is N/A, which is lower than the forecast US Health Information Services industry average of 17.97%.

What is SOLV's Price Target?

According to 8 Wall Street analysts that have issued a 1 year SOLV price target, the average SOLV price target is $90.50, with the highest SOLV stock price forecast at $105.00 and the lowest SOLV stock price forecast at $60.00.

On average, Wall Street analysts predict that Solventum's share price could reach $90.50 by Mar 24, 2027. The average Solventum stock price prediction forecasts a potential upside of 38.59% from the current SOLV share price of $65.30.

What is SOLV's Earnings Per Share (EPS) forecast for 2026-2028?

(NYSE: SOLV) Solventum's current Earnings Per Share (EPS) is $8.94. On average, analysts forecast that SOLV's EPS will be $6.57 for 2026, with the lowest EPS forecast at $6.19, and the highest EPS forecast at $6.84. On average, analysts forecast that SOLV's EPS will be $7.18 for 2027, with the lowest EPS forecast at $6.44, and the highest EPS forecast at $7.94. In 2028, SOLV's EPS is forecast to hit $7.91 (min: $6.96, max: $9.07).

What is SOLV's forecast return on equity (ROE) for 2026-2029?

(NYSE: SOLV) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.